

URGENT
PRESS RELEASE



Wockhardt Limited
Wockhardt Towers
Bandra Kurla Complex
Bandra (East), Mumbai 400
051, India
Tel.: +91 22 2653 4444
Fax: +91 22 2653 4242
Website: www.wockhardt.com

Wockhardt gets US FDA nod to enter the US\$ 2.6 billion Norvasc market

Wockhardt gets US FDA nod to enter the US\$ 2.6 billion Norvasc market Launch of anti-hypertensive Amlodipine tablets

Mumbai, 18 Sep,2007

Pharmaceutical and biotechnology major Wockhardt is all set to launch Amlodipine tablets in the US market. The tablets to be marketed are in strengths of 2.5mg, 5mg and 10mg Amlodipine besylate, which is used for treating hypertension and other related cardiac ailments. Amlodipine is the generic name for the brand Norvasc, sold in the US by Pfizer Inc. As per IMS, the US market for Amlodipine tablets is about \$2.6 billion equivalent to 1.7 billion tablets.

“Wockhardt is gaining a very strong position in several other cardiovascular products, like Enalapril and Captopril. With Amlodipine, we will reinforce our robust cardiovascular portfolio”, said Wockhardt Chairman Habil Khorakiwala. “This rapid increase in our US product portfolio is enabling us to synergistically gain market share across products”.

The Amlodipine tablets are manufactured at the US FDA certified formulation plant at Waluj, Maharashtra. The product was developed in-house.

Wockhardt Limited is a global pharmaceutical and biotechnology major with an innovative research and development programme. Wockhardt has global footprints including UK, Ireland, France, Germany and USA. Wockhardt employs 5500 people worldwide belonging to 14 different nationalities.

**For more information, visit www.wockhardt.com
Corporate Relations Department**